Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma

Experimental and Molecular Pathology

Volumn 90, Issue 3, 2011, Pages 312-317

  Erdem, Havva ^a   Gundogdu Cemal C ^b   Üipal, Sare ^b  

^a DUZCE UNIVERSITY   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

Author keywords

E cadherin; Prognostic factors

Indexed keywords

CYCLOOXYGENASE 2; UVOMORULIN; VASCULOTROPIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PROGNOSIS; STEREOLOGY; THYROID PAPILLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, PAPILLARY; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID GLAND; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79953745315     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.01.008     Document Type: Article

References (36)

1. Bozbora A., Erbil Y., Türe N., Barbaros U., Kaya H., Kapran Y., Özarmag S. Role of vascular endothelial growth factor in the prognosis of papillary thyroid cancer. Endokrinol. Diyalog 2004, Cilt 1(SayĨ 3).
2. Bracham D.G. Molecular biology head and neck cancer. Semin. Oncol. 1994, 21:320-329.
3. Bunone G., Vigneri P., Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 1999, 155:1967-1976.
4. Chang S.H., Liu C.H., Conway R., Han D.K., Nithipatikom K., Trifan O.C., Lane T.F., Hla T. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. PNAS 2004, 101:591-596.
5. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107(4):1183-1188. (Oct).
6. Fellmer P.T., Sato K., Tanaka R., et al. Vascular endothelial growth factors-C gene expression in papillary and follicular thyroid carcinomas. Surgery 1999, 126:1056-1061.
7. Fenton C., Patel A., Dinauer C., Robie D.K., Tuttle R.M., Francis G.L. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000, 10:349-357.
8. Ferhunde DizdaroǦlu, 2005. Dialogue of Endocrine Diyalog, 2: 2, 20.
9. Figge J. Molecular pathogenesis of thyroid cancer. Thyroid Cancer: A Comprehensive Guide to Clinical Management 2000, 57-75. Humana Press, Tatowa New Jersey, (ch 6). L. Wartofsky (Ed.).
10. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5:37-44.
11. Hussain T., Gupta S., Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 2003, 191:125-135.
12. Ito Y., Yoshida H., Nakano K., Takamura Y., Miya A., Kobayashi K., Yokozawa T., Atsuzuka F., Matsuura N., Kuma K., Miyauchi A. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 2003, 42:492-497.
13. Jiang J.B., Li X.M., Zhang W.D., et al. relationship of vascular endothelial growth factor-C and lymphangiogenesis with development and prognosis of colon cancer. Cancer 2005, 8:516-519.
14. Kakiuchi Y., Tsuji S., Tsujii M., Murata H., Kawai N., Yasumaru M., Kimura A., Komori M., Irie T., Miyoshi E., Sasaki Y., Hayashi N., Kawano S., Hori M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res. 2002, 62(5):1567-1572. (Mar 1).
15. Kefeli M., Karagöz F., Barǧǧ S., Yǧldǧz L., AydĨn O., Kandemir B. E-Cadherin and Ki-67 Expression in colorectal carcinomas and their relationship with stage, histological subtype and grade. Turk. J. Pathol. Patoloji Derg. 2005, 21(1-2):8-10.
16. Kiliçarslan Akkaya B., Ogus M., ArÌcÌ C., Pestereli H.E., Cakir M., Karpuzoglu G. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 2003, 111:439-443.
17. Kukora J.S. Thyroid Cancer. Current Surgical Treatment 2001, 11:583-589. Europe Medicine Publishing Firm, Igravestanbul. J.L. Cameron (Ed.).
18. Linderholm B., Grankvist K., Wilking N., et al. Correlation of vascular endothelial growth factor content with recurrences survival and first relapse site in primary node positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 2000, 18:1423-1431.
19. Morris C.D., Armstrong G.R., Bigley G., Green H., Attwood S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-denocarcinoma sequence. Am. J. Gastroenterol. 2001, 96(4):990-996. (Apr).
20. Naito A., Iwase H., Kuzushima T., Nakamura T., Kobayashi S. Clinical significance of e-cadherin expression in thyroid neoplasms. J. Surg. Oncol. 2001, 76(3):176-180. (Mar).
21. Niki T., Iba S., Tokunou M., et al. Expression of vascular endothelial growth factors A, B, C and D and their relationships to lymph node status in lung adenocarcinoma. Clin. Cancer Res. 2000, 6:2431-2439.
22. Nithipatikom K., Isbell Ma, Lindholm P.F., Balla A.K., Kaul S., Campell W.B. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin. Exp. Metastasis 2002, 19:593-601.
23. Reddy B.S., Rao C.V., Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996, 56(20):4566-4569. (Oct 15).
24. Ristimaki A., Nieminen O., Saukkonen K., Hotakainen K., Nordling S., Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am. J. Pathol. 2001, 158(3):849-853.
25. Rocha A.S., Soares P., Fonseca E., Cameselle-Teijeiro J., Oliveira M.C., Sobrinho-Simoes M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 2003, 42:580-587.
26. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55(17):3785-3789. (Sep 1).
27. Scheumman G.F., Hoang-Vu C., Cetin Y., Gimm O., Behrends J., von Wasielewski R., Georgii A., Birchmeier W., von Zur Muhlen A., Dralle H. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J. Clin. Endocrinol. Metab. 1995, 80:2168-2172.
28. Shamma A., Yamamato H., Doki Y., Okami J., Kondo M., Fujiwara Y., Yano M., Inoue M., Matsuura N., Shiozaki H., Monden M. Up-regulation of Cyclooxygenase-2 squamous carcinogenesis of the esophagus. Clin. Cancer Res. 2000, 6:1229-1238.
29. Siironen P., Ristimaki A., Nordling S., Louhimo J., Haapiainen R., Haglund C. Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology 2004, 44:490-497.
30. Siironen P., Louhimo J., Nordling S., Ristimäki A., Mäenpää H., Haapiainen R., Haglund C. Prognostic Factors ∞n Papillary Thyroid Cancer: An Evaluation Of 601 Consecutive Patients. Tumour Biol. 2005, 26(2):57-64. (Mar-Apr).
31. Souza R.F., Shewmake K., Beer D.G., Cryer B., Spechler S.J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000, 60(20):5767-5772. (Oct 15).
32. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., Soslow R.A., Masferrer J.L., Woerner B.M., Koki A.T., Fahey T.J. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res. 1999, 59:987-990.
33. Von Wasielewski R., Rhein A., Werner M., Scheumann G.F., Dralle H., Potter E., Brabant G., Georgii A. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res. 1997, 57:2501-2507.
34. Wendum D., Masliah J., Trugnan G., Flejou J.F. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch. 2004, 445:327-333.
35. Yoshimura R., Matsuyama M., Kawahito Y., Tsuchida K., Kuratsukuri K., Takemoto Y., Mitsuhashi M., Sano H., Nakatani T. Study of cyclooxygenase-2 in renal cell carcinoma. Int. J. Mol. Med. 2004, 13:229-233.
36. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E. Schror. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999, 59(1):198-204. (Jan 1).